ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
Currency in TWD. All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue--373,018-
Cost of Revenue--4,038-
Gross Profit--368,980-
Operating Expenses
Research Development959,099920,311425,296210,471
Selling General and Administrative316,755265,321224,721223,690
Non Recurring----
Others----
Total Operating Expenses1,275,8541,185,632654,055434,161
Operating Income or Loss-1,275,854-1,185,632-281,037-434,161
Income from Continuing Operations
Total Other Income/Expenses Net5,330-22,788-11,288-16,466
Earnings Before Interest and Taxes-1,275,854-1,185,632-281,037-434,161
Interest Expense-14,820-12,623-16,932-33,376
Income Before Tax-1,270,524-1,208,420-292,325-450,627
Income Tax Expense435---
Minority Interest----
Net Income From Continuing Ops-1,270,959-1,208,420-292,325-450,627
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-1,270,959-1,208,420-292,325-450,627
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-1,270,959-1,208,420-292,325-450,627